Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. Jan. 17, 2019. Nicholas Berg.

Executive Summary

New Mexican president Andrés Manuel López Obrador, a member of the National Regeneration Movement (MORENA) party, has swept the office on an anticorruption platform. Some observers expect his efforts to include reforms and increased regulation touching the medical device sector. Nicholas Berg, an attorney with Ropes & Gray, said that in the past Mexico has made limited efforts to combat public corruption. See his advice for medtech companies planning on doing business in Mexico here.

“In particular, medtech companies should be cautious and implement stringent oversight over third-party consultants, intermediaries, agents, distributors, and others that negotiate or interact with Mexican government officials or representatives of state-owned entities, as these types of relationships have proved fertile ground for FCPA cases in recent years, as have interactions with customs officials." —Nicholas Berg, attorney, Ropes & Gray

Click here for a free trial of Medtech Insight

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel